# Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

> **NCT02684084** · PHASE4 · TERMINATED · sponsor: **North Toronto Eye Care Laser and Eye Specialists** · enrollment: 5 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ozurdex
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT02684084
- **Lead sponsor:** North Toronto Eye Care Laser and Eye Specialists
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study revised significantly. New trial to be launched.
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684084, "Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02684084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*